INBX Inhibrx: Earnings per share for the last 12 months

This daily price chart for Inhibrx Biosciences (INBX) EPS (TTM) captures the metric at 11.60. The business's competitiveness is bolstered by a solid cash reserve and patent protection for early oncology drugs. Inhibrx Biosciences develops multipurpose protein systems where specialized antibodies create a closed therapeutic cycle. Revenue is generated through the sale of unique protein treatments for orphan diseases via government funds and insurers.
INBX (Inhibrx): analytical breakdowns and indicator data

The investment attractiveness of Inhibrx Biosciences (INBX) is based on the commercialization potential of innovative protein drugs for oncology therapy. This indicator measures the dynamics of net income per share over twelve months, reflecting the monetization efficiency of R&D assets. By analyzing the current eps YoY ttm trajectory, an investor can promptly identify business micro-slowdowns against a backdrop of high borrowing costs. Stable growth of this metric confirms capital resilience and the success of drug development.